Introduction: Enkephalins, endogenous opioid peptides, are involved in the regulation of renal function. One derived molecule, proenkephalin A, also known as penKid, has been demonstrated to be a reliable biomarker for kidney function and its plasma concentration correlates with measured glomerular filtration rate. penKid is used for prediction and diagnosis of AKI and need of renal replacement therapy (RRT). penKid has also been used to predict the successful weaning from RRT in patients with AKI. Whether the concentration of penKid is affected or not by RRT is a controversial point and there are no studies describing the kinetics of the molecule in such conditions. The low molecular weight (4.5 kDa) would imply free removal by the glomerulus and the dialysis membranes. During RRT, this reduction could not be detected in clinical practice due to the complex kinetics involving either low dialytic clearance or increased production in response to impaired kidney function. The aim of this study was to determine the sieving coefficient and the diffusive clearance of the penKid molecule in conditions of in vitro continuous veno-venous hemofiltration (CVVH) and continuous veno-venous hemodialysis (CVVHD), respectively, and also the penKid removal ratio in conditions of in vitro hemoadsorption (HA) using a synthetic microporous resin. Methods: Blood spiked with a lyophilized penKid peptide solved in 20 mm dipotassium phosphate and 6 mm disodium EDTA [pH 8] to reach target concentrations is used as testing solution. In each experiment, the blood batch was adjusted at a volume of 1,000 mL, maintained at 37°, and continuously stirred. Samples were collected from blood, ultrafiltrate, and spent dialysate at different times during the experiments. Sieving, clearance, and removal ratio were calculated. Results: Significant removal of penKid was observed in CVVH (sieving 1.04 ± 0.27), in CVVHD (clearance 23.08 ± 0.89), and in HA (removal ratio 76.1 ± 1% after 120 min). Conclusion: penKid is effectively removed by extracorporeal therapies. In presence of anuria, penKid generation kinetics can be calculated based on extracorporeal removal and volume variation. In steady state conditions, declining values may be the result of an initial renal function recovery and may suggest discontinuation and successful liberation from RRT.

Journal Section:
Critical Care Nephrology – Research Article
Keywords:
Acute kidney injury, Extracorporeal therapies, Continuous renal replacement therapy, CRRT discontinuation
1.
Denning
GM
,
Ackermann
LW
,
Barna
TJ
,
Armstrong
JG
,
Stoll
LL
,
Weintraub
NL
, et al.
Proenkephalin expression and enkephalin release are widely observed in non-neuronal tissues
.
Peptides
.
2008
;
29
(
1
):
83
–
92
.
Google Scholar
 
2.
Zoccali
C
,
Ciccarelli
M
,
Mallamaci
F
,
Maggiore
Q
,
Lotti
M
,
Zucchelli
GC
.
Plasma met-enkephalin and leu-enkephalin in chronic renal failure
.
Nephrol Dial Transpl
.
1987
;
1
(
4
):
219
–
22
.
Google Scholar
 
3.
Erdös
EG
,
Johnson
AR
,
Boyden
NT
.
Hydrolysis of enkephalin by cultured human endothelial cells and by purified peptidyl dipeptidase
.
Biochem Pharmacol
.
1978
;
27
(
5
):
843
–
8
.
Google Scholar
 
4.
Ernst
A
,
Köhrle
J
,
Bergmann
A
.
Proenkephalin A 119-159, a stable proenkephalin A precursor fragment identified in human circulation
.
Peptides
.
2006
;
27
(
7
):
1835
–
40
.
Google Scholar
 
5.
Donato
LJ
,
Meeusen
JW
,
Lieske
JC
,
Bergmann
D
,
Sparwaßer
A
,
Jaffe
AS
.
Analytical performance of an immunoassay to measure proenkephalin
.
Clin Biochem
.
2018
;
58
:
72
–
7
.
Google Scholar
 
6.
Beunders
R
,
Struck
J
,
Wu
AHB
,
Zarbock
A
,
Di Somma
S
,
Mehta
RL
, et al.
Proenkephalin (PENK) as a novel biomarker for kidney function
.
J Appl Lab Med
.
2017
;
2
(
3
):
400
–
12
.
Google Scholar
 
7.
Khorashadi
M
,
Beunders
R
,
Pickkers
P
,
Legrand
M
.
Proenkephalin: a new biomarker for glomerular filtration rate and acute kidney injury
.
Nephron
.
2020
;
144
(
12
):
655
–
61
.
Google Scholar
 
8.
Kim
H
,
Hur
M
,
Lee
S
,
Marino
R
,
Magrini
L
,
Cardelli
P
, et al.
Proenkephalin, neutrophil gelatinase-associated lipocalin, and estimated glomerular filtration rates in patients with sepsis
.
Ann Lab Med
.
2017
;
37
(
5
):
388
–
97
.
Google Scholar
 
9.
Rosenqvist
M
,
Bronton
K
,
Hartmann
O
,
Bergmann
A
,
Struck
J
,
Melander
O
.
Proenkephalin a 119-159 (penKid) - a novel biomarker for acute kidney injury in sepsis: an observational study
.
BMC Emerg Med
.
2019
;
19
(
1
):
75
.
Google Scholar
 
10.
Gayat
E
,
Touchard
C
,
Hollinger
A
,
Vieillard-Baron
A
,
Mebazaa
A
,
Legrand
M
, et al.
Back-to-back comparison of penKID with NephroCheck® to predict acute kidney injury at admission in intensive care unit: a brief report
.
Crit Care
.
2018
;
22
(
1
):
24
.
Google Scholar
 
11.
Caironi
P
,
Latini
R
,
Struck
J
,
Hartmann
O
,
Bergmann
A
,
Bellato
V
, et al.
Circulating proenkephalin, acute kidney injury, and its improvement in patients with severe sepsis or shock
.
Clin Chem
.
2018
;
64
(
9
):
1361
–
9
.
Google Scholar
 
12.
Dépret
F
,
Hollinger
A
,
Cariou
A
,
Deye
N
,
Vieillard-Baron
A
,
Fournier
M-C
, et al.
Incidence and outcome of subclinical acute kidney injury using penKid in critically ill patients
.
Am J Respir Crit Care Med
.
2020
;
202
(
6
):
822
–
9
.
Google Scholar
 
13.
Zarbock
A
,
Nadim
MK
,
Pickkers
P
,
Gomez
H
,
Bell
S
,
Joannidis
M
, et al.
Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup
.
Nat Rev Nephrol
.
2023
;
19
(
6
):
401
–
17
.
Google Scholar
 
14.
von Groote
T
,
Albert
F
,
Meersch
M
,
Koch
R
,
Porschen
C
,
Hartmann
O
, et al.
Proenkephalin A 119-159 predicts early and successful liberation from renal replacement therapy in critically ill patients with acute kidney injury: a post hoc analysis of the ELAIN trial
.
Crit Care
.
2022
;
26
(
1
):
333
.
Google Scholar
 
15.
von Groote
T
,
Albert
F
,
Meersch
M
,
Koch
R
,
Gerss
J
,
Arlt
B
, et al.
Evaluation of Proenkephalin A 119-159 for liberation from renal replacement therapy: an external, multicenter pilot study in critically ill patients with acute kidney injury
.
Crit Care
.
2023
;
27
(
1
):
276
.
Google Scholar
 
16.
Ankawi
G
,
Fan
W
,
Pomarè Montin
D
,
Lorenzin
A
,
Neri
M
,
Caprara
C
, et al.
A new series of sorbent devices for multiple clinical purposes: current evidence and future directions
.
Blood Purif
.
2019
;
47
(
1–3
):
94
–
100
.
Google Scholar
 
17.
Lorenzin
A
,
de Cal
M
,
Marcello
M
,
Sorbo
D
,
Copelli
S
,
Ronco
C
, et al.
Vancomycin adsorption during in vitro model of hemoperfusion with mini-module of HA380 cartridge
.
Blood Purif
.
2023
;
52
(
2
):
174
–
82
.
Google Scholar
 
18.
Ronco
C
,
Neri
M
,
Lorenzin
A
,
Garzotto
F
,
Clark
WR
.
Multidimensional classification of dialysis membranes
.
Contrib Nephrol
.
2017
;
191
:
115
–
26
.
Google Scholar
 
19.
Ronco
C
,
Clark
WR
.
Haemodialysis membranes
.
Nat Rev Nephrol
.
2018
;
14
(
6
):
394
–
410
.
Google Scholar
 
20.
Bellomo
R
,
Ronco
C
.
Clinical applications of adsorption: the new era of Jafron sorbents
.
Contrib Nephrol
.
2023
;
200
:
25
–
31
.
Google Scholar
 
21.
Ronco
C
,
Bellomo
R
.
Hemoperfusion: technical aspects and state of the art
.
Crit Care
.
2022
;
26
(
1
):
135
.
Google Scholar
 
22.
Bellomo
R
,
Mehta
RL
,
Forni
LG
,
Zarbock
A
,
Ostermann
M
,
Ronco
C
, et al.
Hemoadsorption
.
Clin J Am Soc Nephrol
.
2024
;
19
(
6
):
803
–
6
.
Google Scholar
 
23.
Fealy
N
,
Aitken
L
,
du Toit
E
,
Bailey
M
,
Baldwin
I
.
Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate
.
Crit Care Resusc
.
2018
;
20
(
1
):
41
–
7
.
Google Scholar
 
24.
Ronco
C
,
Brendolan
A
,
Bragantini
L
,
Fabris
A
,
Feriani
M
,
Chiaramonte
S
, et al.
Solute and water transport during continuous arteriovenous hemofiltration (CAVH)
.
Int J Artif Organs
.
1987
;
10
(
3
):
179
–
84
.
Google Scholar
 
25.
Leypoldt
JK
,
Storr
M
,
Agar
BU
,
Boschetti-de-Fierro
A
,
Bernardo
AA
,
Kirsch
AH
, et al.
Intradialytic kinetics of middle molecules during hemodialysis and hemodiafiltration
.
Nephrol Dial Transpl
.
2019
;
34
(
5
):
870
–
7
.
Google Scholar
 
© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.